Clearmind Medicine Inc. (NASDAQ: CMND) released a statement regarding President Trump's executive order signed April 18, 2026, titled "Accelerating Medical Treatments for Serious Mental Illness." The order directs the FDA to prioritize review processes for certain psychedelic drugs designated as breakthrough therapies and expands patient access pathways.

The Vancouver-based clinical-stage biotech company develops non-hallucinogenic, neuroplastogen-derived therapeutics. Chief Executive Officer Dr. Adi Zuloff-Shani said the executive order "highlights the growing acknowledgment at the highest levels of the urgent need to remove unnecessary barriers and deliver innovative treatments to millions of Americans, especially veterans, suffering from treatment-resistant PTSD, depression, and alcohol use disorder."

In February 2026, Clearmind's proprietary compound MEAI (5-methoxy-2-aminoindane) was named in bipartisan congressional legislation H.R. 7091, the Expanding Veterans' Access to Emerging Treatments Act. The proposed legislation would support VA clinical trials and expanded access protocols for therapies targeting alcohol use disorder.

The company is conducting FDA-approved Phase I/IIa clinical trials of CMND-100 (MEAI) for alcohol use disorder at Yale School of Medicine and Johns Hopkins University. Clearmind holds 31 granted patents across 19 patent families in its intellectual property portfolio.

The information is based on a company press release statement.